Titan Company Limited (NSE: TITAN): Titan has reported a significant 25% increase in standalone revenue for the fourth quarter, driven by strong sales in premium jewellery and gold coins. This growth has surpassed analyst expectations, leading to an upgrade in the company's rating by Axis Capital from "reduce" to "add."
Bharti Airtel Limited (NSE: BHARTIARTL): On April 8, 2025, Bharti Airtel's shares rose by 1.90% to ₹1,720.00, outperforming the broader market. Despite this gain, the stock remains 3.31% below its 52-week high of ₹1,778.95, suggesting potential room for growth.
Tata Steel Limited (NSE: TATASTEEL): Tata Steel's shares experienced a modest increase of 0.46% on April 8, closing at ₹130.20. However, the stock is still significantly below its 52-week high of ₹184.60, indicating a potential opportunity for investors considering the company's future prospects.
Reliance Industries Limited (NSE: RELIANCE): Reliance Industries saw its shares rise by 1.39% to ₹1,182.40 on April 8. Despite this uptick, the stock remains 26.51% below its 52-week high of ₹1,608.95, suggesting potential for recovery.
NTPC Limited (NSE: NTPC): NTPC's shares increased by 0.84% to ₹352.95 on April 8. The stock is currently 21.27% below its 52-week high of ₹448.30, indicating possible growth opportunities as the company continues its operations in the energy sector.
CRISIL Limited (NSE: CRISIL): CRISIL is set to trade ex-dividend on April 11, 2025. Investors may consider this date when evaluating potential dividend income from the stock.
ICICI Bank Limited (NSE: ICICIBANK): Motilal Oswal Financial Services has recommended ICICI Bank as a stock to buy and hold in portfolios for April, citing strong fundamentals and growth prospects.
Investors should conduct thorough research and consider their risk tolerance before making investment decisions, as stock market investments are subject to market risks.
Source: Taken from multiple websites
Disclaimer
The information provided in this media release is based on current facts and circumstances as of the date of publication. It may contain forward-looking statements, including but not limited to projections, expectations, or assumptions about future events or performance. These forward-looking statements are subject to risks, uncertainties, and other factors that may cause actual results to differ materially from those anticipated. Hester Biosciences Ltd does not undertake any obligation to update, revise, or correct any forward-looking statements based on new information or future events. This release is intended for informational purposes only and does not constitute financial, investment, or professional advice.